Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Anadys hepatitis candidate enters clinic
ANA975 is an oral prodrug of Anadys’ proprietary small molecule compound isatoribine, an agonist of toll-like receptor 7 (TLR7). Results from clinical trials of isatoribine have demonstrated a
ANA975 is an oral prodrug of Anadys’ proprietary small molecule compound isatoribine, an agonist of toll-like receptor 7 (TLR7). Results from clinical trials of isatoribine have demonstrated a
Although specific financial terms were not announced, Schering will receive an upfront fee, milestone payments and royalties on sales of any compounds successfully commercialized under the agreement. ADP
Under the terms of the agreement, Savient, Teva and Novo Nordisk have granted each other cross-licenses to any patents covering the human growth hormone (hGH) active ingredient. An
The phase I component of the new study is a multi-center, multi-national trial which will first determine the dose, safety, tolerability, pharmacokinetics and preliminary efficacy of PT-523 in
The primary goal of this trial is to assess the safety and effectiveness of REN-1654 in treating acute pain in post-herpetic neuralgia (PHN) patients. “We are pleased to
Verapamil hydrochloride (HCI), a calcium channel blocker, is indicated for the management of essential hypertension. Par expects to begin shipment of the product in early 2005 and, based
The transaction significantly expands Valeant’s business in North America and enhances the company’s neurology franchise through the acquisition of key products and a specialized neurology sales organization. The
The FDA has determined that Ranbaxy’s formulation can be expected to have the same therapeutic effect as an equivalent dose of Biaxin XL filmtab extended release tablets 500mg
Pfizer said that it vigorously refutes claims by Public Citizen that safety data from a 1999 Celebrex study in Alzheimer’s patients were “undisclosed.” The study, Pfizer explained, was
Nastech developed Nascobal nasal spray (Cyanocobalamin, USP) as an alternative to Nascobal gel for intranasal administration, an FDA approved product launched in 1997. Worldwide marketing rights to both